Skip to main content
Fig. 5 | Clinical Epigenetics

Fig. 5

From: A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML

Fig. 5

Time-course collection of peripheral blood samples in Arm A reveals consistent decreases in promoter methylation at relevant transcription start sites over treatment in all responders, as well as a reversal of this decrease in the sole non-responsive patient (1006-1004). A distinct uptick in the patient’s promoter methylation from day 14 to 21 is noted, which corresponded clinically to the patient’s disease progression

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us